Skip to menu Skip to content Skip to footer
Dr

Amelia Fotheringham

Email: 

Overview

Background

After completing an honours year in genetics in the lab of Professor Paul Ebert (The University of Queensland), Dr Fotheringham obtained a research assistant position in the field of diabetes, sparking a passionate interest in diabetes and diabetes complications, particularly diabetic nephropathy. This led her to undertake and complete a PhD, examining the influence of dietary factors, in particularly advanced glycation end products and macronutrients on renal function in diabetes and aging. Since completing her PhD in 2020, Dr Amelia Fotheringham has worked as a Research Officer in the Glycation and Diabetes Complications Laboratory at Mater Research-UQ. Here she has undertaken projects examining novel treatments for mitochondrial dysfunction in diabetic nephropathy and targeting the AGE-RAGE pathway for type 1 diabetes prevention.

Availability

Dr Amelia Fotheringham is:
Available for supervision

Works

Search Professor Amelia Fotheringham’s works on UQ eSpace

46 works between 2013 and 2024

21 - 40 of 46 works

2018

Book Chapter

Dietary AGEs in the development and progression of chronic kidney disease

Fotheringham, Amelia K., Gallo, Linda A. and Forbes, Josephine M. (2018). Dietary AGEs in the development and progression of chronic kidney disease. Dietary AGEs and their role in health and disease. (pp. 213-224) edited by Jaime Uribarri. Boca Raton, FI, United States: CRC Press. doi: 10.1201/9781315120041

Dietary AGEs in the development and progression of chronic kidney disease

2018

Conference Publication

Glucose and insulin profiles during an oral glucose tolerance test (oGTT) are similar between fed and fasted states in a cohort of university students

Akison, Lisa K., Gallo, Linda A., Barclay, Johanna L., Zhuang, Aowen, Chen, Cortina, Fotheringham, Amelia K. and Moritz, Karen M. (2018). Glucose and insulin profiles during an oral glucose tolerance test (oGTT) are similar between fed and fasted states in a cohort of university students. Joint Annual Scientific Meetings of Endocrine Society of Australia (ESA) and Society for Reproductive Biology (SRB), Perth, Australia, 27-30 August 2017. Chichester, West Sussex, United Kingdom: Wiley-Blackwell.

Glucose and insulin profiles during an oral glucose tolerance test (oGTT) are similar between fed and fasted states in a cohort of university students

2017

Journal Article

Perinatal exposure to high dietary advanced glycation end products in transgenic NOD8.3 mice leads to pancreatic beta cell dysfunction

Borg, Danielle J., Yap, Felicia Y. T., Keshvari, Sahar, Simmons, David G., Gallo, Linda A., Fotheringham, Amelia K., Zhuang, Aowen, Slattery, Robyn M., Hasnain, Sumaira Z., Coughlan, Melinda T., Kantharidis, Phillip and Forbes, Josephine M. (2017). Perinatal exposure to high dietary advanced glycation end products in transgenic NOD8.3 mice leads to pancreatic beta cell dysfunction. Islets, 10 (1), 10-24. doi: 10.1080/19382014.2017.1405189

Perinatal exposure to high dietary advanced glycation end products in transgenic NOD8.3 mice leads to pancreatic beta cell dysfunction

2017

Journal Article

Targeted mitochondrial therapy using MitoQ shows equivalent renoprotection to angiotensin converting enzyme inhibition but no combined synergy in diabetes

Ward, Micheal S.., Flemming, Nicole B., Gallo, Linda A., Fotheringham, Amelia K., McCarthy, Domenica A., Zhuang, Aowen, Tang, Peter H., Borg, Danielle J., Shaw, Hannah, Harvie, Benjamin, Briskey, David R., Roberts, Llion A., Plan, Manuel R., Murphy, Michael P., Hodson, Mark P. and Forbes, Josephine M. (2017). Targeted mitochondrial therapy using MitoQ shows equivalent renoprotection to angiotensin converting enzyme inhibition but no combined synergy in diabetes. Scientific Reports, 7 (1) 15190, 15190. doi: 10.1038/s41598-017-15589-x

Targeted mitochondrial therapy using MitoQ shows equivalent renoprotection to angiotensin converting enzyme inhibition but no combined synergy in diabetes

2017

Conference Publication

Using the Geometric Framework to Explore the Longitudinal Effects of Dietary Macronutrient Consumption On Markers of Kidney Aging

Fotheringham, A. K., Solon-Biet, S. M., Mcmahon, A. C., Ballard, W. O., Ruohonen, K., Borg, D. J., Raubenheimer, D., Le Couteur, D. G., Simpson, S. J. and Forbes, J. M. (2017). Using the Geometric Framework to Explore the Longitudinal Effects of Dietary Macronutrient Consumption On Markers of Kidney Aging. HOBOKEN: WILEY.

Using the Geometric Framework to Explore the Longitudinal Effects of Dietary Macronutrient Consumption On Markers of Kidney Aging

2017

Conference Publication

Lifetime dietary macronutrient intake ratios alter kidney function and structure into old age

Fotheringham, A. K., Solon-Biet, S. M., McMahon, A. C., Ballard, W. O., Ruohonen, K., Borg, D. J., Raubenheimer, D., Le Couteur, D. G., Simpson, S. J. and Forbes, J. M. (2017). Lifetime dietary macronutrient intake ratios alter kidney function and structure into old age. 53rd Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), Lisbon Portugal, Sep 11-15, 2017. NEW YORK: SPRINGER.

Lifetime dietary macronutrient intake ratios alter kidney function and structure into old age

2017

Journal Article

Vascular complications in diabetes: old messages, new thoughts

Forbes, Josephine M. and Fotheringham, Amelia K. (2017). Vascular complications in diabetes: old messages, new thoughts. Diabetologia, 60 (11), 2129-2138. doi: 10.1007/s00125-017-4360-x

Vascular complications in diabetes: old messages, new thoughts

2016

Conference Publication

Understanding Novel Genetic Factors Underlying Circulating Cystatin C and Kidney Function

Fotheringham, A., Balmer, L., Morahan, G. and Forbes, J. (2016). Understanding Novel Genetic Factors Underlying Circulating Cystatin C and Kidney Function. HOBOKEN: WILEY-BLACKWELL.

Understanding Novel Genetic Factors Underlying Circulating Cystatin C and Kidney Function

2016

Journal Article

Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice

Gallo, Linda A., Ward, Micheal S., Fotheringham, Amelia K., Zhuang, Aowen, Borg, Danielle J., Flemming, Nicole B., Harvie, Ben M., Kinneally, Toni L., Yeh, Shang-Ming, McCarthy, Domenica A., Koepsell, Hermann, Vallon, Volker, Pollock, Carol, Panchapakesan, Usha and Forbes, Josephine M. (2016). Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Scientific Reports, 6 (1) 26428, 28124. doi: 10.1038/srep26428

Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice

2016

Conference Publication

The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic Db/Db Mice

Gallo, Linda A., Ward, Micheal S., Fotheringham, Amelia K., Zhuang, Aowen, Koepsell, Hermann, Vallon, Volker, Pollock, Carol, Panchapakesan, Usha and Forbes, Josephine M. (2016). The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic Db/Db Mice. Experimental Biology 2016 Meeting, San Diego, CA United States, 1-5 April 2016. Hoboken, NJ United States: John Wiley & Sons. doi: 10.1096/fasebj.30.1_supplement.740.18

The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic Db/Db Mice

2016

Conference Publication

The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic <i>Db</i>/<i>Db</i> Mice

Gallo, Linda A., Ward, Micheal S., Fotheringham, Amelia K., Zhuang, Aowen, Koepsell, Hermann, Vallon', Volker, Pollock, Carol, Panchapakesan, Usha and Forbes, Josephine M. (2016). The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic Db/Db Mice. Experimental Biology Meeting, San Diego Ca, Apr 02-06, 2016. BETHESDA: FEDERATION AMER SOC EXP BIOL.

The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic <i>Db</i>/<i>Db</i> Mice

2015

Conference Publication

Human soluble receptor for advanced glycation end products therapy reduces autoimmune diabetes in the non-obese diabetic mouse

Leung, S. S.-Y., Borg, D. J., McCarthy, D., Zhuang, A., Fotheringham, A., Di Trapani, G., Groop, P.-H., Knip, M. and Forbes, J. (2015). Human soluble receptor for advanced glycation end products therapy reduces autoimmune diabetes in the non-obese diabetic mouse. Joint Annual Conference of the International Society for Pediatric and Adolescent Diabetes and Australasian Paediatric Endocrine Group (ISPAD+APEG 2015), Brisbane, QLD Australia, 7-10 October 2015. Hoboken, NJ USA: Wiley-Blackwell Publishing. doi: 10.1111/pedi.12309

Human soluble receptor for advanced glycation end products therapy reduces autoimmune diabetes in the non-obese diabetic mouse

2015

Conference Publication

Short-term alagebrium chloride (ALT-711) therapy pre-diabetes for the treatment of Type I Diabetes

Borg, D. J., McCarthy, D., Reeves, P., Ward, M. S., Fotheringham, A. K., Gallo, L. A., Harcourt, B. E., Agrawal, N., Steptoe, R. and Forbes, J. M. (2015). Short-term alagebrium chloride (ALT-711) therapy pre-diabetes for the treatment of Type I Diabetes. Immunology of Diabetes Society 14th International Congress, Munich, Germany, 12-16 April 2015.

Short-term alagebrium chloride (ALT-711) therapy pre-diabetes for the treatment of Type I Diabetes

2015

Conference Publication

In Db/db mice, Sglt2 inhibition does not improve diabetic nephropathy despite glycaemic improvements

Gallo, L. A., Ward, M. S., Fotheringham, A. K., Pollock, C., Panchapakesan, U. and Forbes, J. M. (2015). In Db/db mice, Sglt2 inhibition does not improve diabetic nephropathy despite glycaemic improvements. 51st Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Canberra, Australia, 7-9 September 2015. Richmond, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/nep.12543

In Db/db mice, Sglt2 inhibition does not improve diabetic nephropathy despite glycaemic improvements

2015

Conference Publication

Delivery of recombinant human soluble receptor for advanced glycation end products delays autoimmune diabetes in the NOD mouse model

Borg, D. J., Leung, S., Zhuang, A., Fotheringham, A., McCarthy, D., Di Trapani, J., Groop, P. -H., Knip, M. and Forbes, J. (2015). Delivery of recombinant human soluble receptor for advanced glycation end products delays autoimmune diabetes in the NOD mouse model. 51st Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), Stockholm, Sweden, 14-18 September 2015. Heidelberg, Germany: Springer. doi: 10.1007/s00125-015-3687-4

Delivery of recombinant human soluble receptor for advanced glycation end products delays autoimmune diabetes in the NOD mouse model

2014

Journal Article

Deletion of bone-marrow-derived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes

Tesch, Greg, Sourris, Karly C., Summers, Shaun A., McCarthy, Domenica, Ward, Micheal S., Borg, Danielle J., Gallo, Linda A., Fotheringham, Amelia K., Pettit, Allison R., Yap, Felicia Y. T., Harcourt, Brooke E., Tan, Adeline L. Y., Kausman, Joshua Y., Nikolic-Paterson, David, Kitching, Arthur R. and Forbes, Josephine M. (2014). Deletion of bone-marrow-derived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes. Diabetologia, 57 (9), 1977-1985. doi: 10.1007/s00125-014-3291-z

Deletion of bone-marrow-derived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes

2014

Conference Publication

Ager1 overexpression in glomerular podocytes results in renal disease which is exacerbated by diabetes

Zhuang, A., Sourris, K. C, Harcourt, B. E, Penfold, S. A., Fotheringham, A. K., McCarthy, D., Schulz, B. and Forbes, J. M. (2014). Ager1 overexpression in glomerular podocytes results in renal disease which is exacerbated by diabetes. 50th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Melbourne VIC, Australia, 25 - 27 August 2014. Richmond, VIC Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/nep.12301

Ager1 overexpression in glomerular podocytes results in renal disease which is exacerbated by diabetes

2014

Conference Publication

Flux of advanced glycation end products across the kidney as a contributor to renal disease in diabetes

Leung, C., Fotheringham, A. K., Zhuang, A., Borg, D. J., Ward, M. S., Coughlan, M. T., Mccarthy, D. A., Gallo, L. A., Harcourt, B. E. and Forbes, J. M. (2014). Flux of advanced glycation end products across the kidney as a contributor to renal disease in diabetes. 50th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Melbourne, Australia, 25–27 August 2014. Richmond Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/nep.12302

Flux of advanced glycation end products across the kidney as a contributor to renal disease in diabetes

2014

Conference Publication

Glyoxalase-1 Inhibition Leads to Podocyte Insulin Resistance and Features Resembling Diabetic Kidney Disease

Gallo, Linda A., Ward, Micheal S., Harcourt, Brooke E., Fotheringham, Amelia K., McCarthy, Domenica A., Penfold, Sally A. and Forbes, Josephine M. (2014). Glyoxalase-1 Inhibition Leads to Podocyte Insulin Resistance and Features Resembling Diabetic Kidney Disease. 14th Asian Pacific Congress of Nephrology, Tokyo, Japan, 14-17 May 2014. Richmond, VIC, Australia: Wiley-Blackwell. doi: 10.1111/nep.12236

Glyoxalase-1 Inhibition Leads to Podocyte Insulin Resistance and Features Resembling Diabetic Kidney Disease

2014

Conference Publication

Mitochondrial targeting of superoxide by Mitoq improves metabolic renal dysfunction

Ward, M. S., Flemming, N. B., Gallo, L. A., Fotheringham, A., Gobe, G., Vesey, D. and Forbes, J. M. (2014). Mitochondrial targeting of superoxide by Mitoq improves metabolic renal dysfunction. 50th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Melbourne Australia, 25–27 August 2014. Richmond Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/nep.12301

Mitochondrial targeting of superoxide by Mitoq improves metabolic renal dysfunction

Funding

Current funding

  • 2023 - 2024
    Targeting the receptor for advanced glycation end products (RAGE) to prevent diabetic kidney disease (Early Career Fellowship)
    Australian Centre for Accelerating Diabetes Innovations
    Open grant
  • 2021 - 2024
    Innovative delivery methods for the biologic soluble RAGE to prevent Type 1 Diabetes
    JDRF Pilot and Innovation Awards
    Open grant

Supervision

Availability

Dr Amelia Fotheringham is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Media

Enquiries

For media enquiries about Dr Amelia Fotheringham's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au